Table 5.
W3-W0 | p | M3-W0 | p | M6-W0 | p | ||||
---|---|---|---|---|---|---|---|---|---|
Group | A | B | A | B | ST | C | |||
N | (92) | (92) | (88) | (81) | (81) | (78) | |||
Treatment use (%) | |||||||||
None | 2.6 | − 16.4 | 0.046 | 3.8 | − 6.3 | ns | − 9.8 | − 21.1 | ns |
Analgesics | 1.6 | 10.3 | 0.046 | 0.6 | − 3.6 | ns | − 3.0 | 0.7 | ns |
NSAIDs | − 1.0 | 0.9 | 0.046 | − 4.2 | 0.6 | ns | − 3.6 | − 2.7 | ns |
Both | − 3.1 | 5.1 | 0.046 | − 0.3 | 5.3 | ns | 0.4 | 3.0 | ns |
Massage | − 13.4 | − 13.8 | 0.012 | − 12.9 | − 4.9 | ns | − 10.1 | − 18.1 | ns |
Rehabilitation | − 19.3 | − 7.9 | ns | − 18.8 | − 10.4 | ns | − 23.3 | − 13.1 | ns |
Topical agents | − 47.0 | − 8.4 | < 0.001 | − 37.8 | − 1.3 | 0.059 | − 50.9 | − 15 | 0.003 |
Group A immediate spa treatment, group B delayed spa treatment, i.e. controls; NSAIDs non-steroidal anti-inflammatory drugs, ns not significant, t test or chi2